PureSinse Inc. has completed its initial Sales License review with Health Canada and has entered into a multi-year agreement with Appletree Medical Group Inc. pursuant to which Appletree will participate and provide lead investigators for the purposes of a real-world evidence-based research study. PureSinse has established capabilities and Standard Operating Procedures to meet licensing requirements for testing in compliance with Good Production Practices, child resistant packaging which meets the requirements of the Food and Drug Regulations. These include packaging, labelling, shipping methods, client registration, ordering and product record keeping systems in accordance with both requirements under the ACMPR and the Cannabis Act, which will be effective as of October 17, 2018.